JPMorgan Chase & Co. Issues Positive Forecast for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN) had its target price hoisted by JPMorgan Chase & Co. from $34.00 to $38.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. HC Wainwright upped their target price on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Truist Financial increased their price target on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 price objective on shares of Septerna in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Septerna Price Performance

Shares of SEPN opened at $23.44 on Tuesday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -21.12 and a beta of 3.46. Septerna has a one year low of $4.66 and a one year high of $32.63. The business has a fifty day moving average of $26.56 and a 200 day moving average of $24.09.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The firm had revenue of $24.12 million during the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. Analysts expect that Septerna will post -7.11 EPS for the current fiscal year.

Insider Transactions at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This represents a 98.89% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. First Light Asset Management LLC bought a new stake in Septerna in the 4th quarter valued at $17,308,000. Primecap Management Co. CA purchased a new stake in Septerna in the 4th quarter worth $15,225,000. Perceptive Advisors LLC purchased a new stake in Septerna in the 2nd quarter worth $5,723,000. Finally, VR Adviser LLC bought a new position in shares of Septerna during the 2nd quarter valued at about $5,713,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.